Three-dimensional psoas muscle volume and longitudinal changes as predictors of outcomes in older patients with advanced pancreatic cancer

Figure 3 Kaplan-Meier curves for overall survival and progression-free survival in enrolled patients with and without sarcopenia. A: The overall survival of the sarcopenic group (dotted blue line) was significantly shorter than that of the non-sarcopenic group (solid orange line) (P < 0.001, log-rank test). The median overall survival was 175 days and 562 days in the sarcopenic and non-sarcopenic groups, respectively; B: The progression-free survival of the sarcopenic group (dotted blue line) was significantly shorter than that of the non-sarcopenic group (solid orange line) (P < 0.001, log-rank test). The median progression-free survival was 88 days in the sarcopenic group and 242 days in the non-sarcopenic group.